» Articles » PMID: 2365280

Risk Factors for the Development of Hepatic Cysts in Autosomal Dominant Polycystic Kidney Disease

Overview
Journal Hepatology
Specialty Gastroenterology
Date 1990 Jun 1
PMID 2365280
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic cysts are a major manifestation of autosomal dominant polycystic kidney disease. This study examined 239 autosomal dominant polycystic kidney disease patients and 189 unaffected family members to define the factors that influence the presence and severity of hepatic cysts. Autosomal dominant polycystic kidney disease patients with hepatic cysts were older than autosomal dominant polycystic kidney disease patients without such cysts (44.6 +/- 1.1 yr vs. 32.9 +/- 1.1 yr; p less than 0.0001). The number of hepatic cysts increased with age (r = 0.43; p less than 0.0001). Women were more likely to have massive hepatic cystic disease (greater than 15 cysts) than men (p less than 0.04). Women also had larger maximal cyst size (4.2 +/- 0.4 cm vs. 2.7 +/- 0.3 cm; p less than 0.004). Women with hepatic cysts were more likely to have been pregnant (p less than 0.001) and to have had more pregnancies (2.9 +/- 0.3 pregnancies vs. 1.6 +/- 0.2 pregnancies; p less than 0.0009). Kidney volume (p less than 0.0001), number of cysts (p less than 0.004), percentage of cystic parenchyma (p less than 0.001) and predominant cyst size (p less than 0.001) were greater and creatinine clearance was lower (64.5 +/- 3.1 ml/min/1.73 m2 vs. 94.5 +/- 3.4 ml/min/1.73 m2; p less than 0.001) in autosomal dominant polycystic kidney disease patients with hepatic cysts. By logistic regression, the frequency of hepatic cysts was related to increased age, increased severity of renal cystic disease and decreased creatinine clearance. Number and size of hepatic cysts correlated with the occurrence of pregnancy, female gender, increased age and severity of the renal lesion.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Liver manifestations in autosomal dominant polycystic kidney disease (ADPKD) and their impact on quality of life.

Arjune S, Todorova P, Bartram M, Grundmann F, Muller R Clin Kidney J. 2025; 18(1):sfae363.

PMID: 40008356 PMC: 11852259. DOI: 10.1093/ckj/sfae363.


Advances and Challenges in Modeling Autosomal Dominant Polycystic Kidney Disease: A Focus on Kidney Organoids.

Gu J, Liu F, Li L, Mao J Biomedicines. 2025; 13(2).

PMID: 40002937 PMC: 11852630. DOI: 10.3390/biomedicines13020523.


Clinical manifestation, epidemiology, genetic basis, potential molecular targets, and current treatment of polycystic liver disease.

Mahboobipour A, Ala M, Safdari Lord J, Yaghoobi A Orphanet J Rare Dis. 2024; 19(1):175.

PMID: 38671465 PMC: 11055360. DOI: 10.1186/s13023-024-03187-w.


Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement.

Righini M, Mancini R, Busutti M, Buscaroli A Int J Mol Sci. 2024; 25(5).

PMID: 38473800 PMC: 10932244. DOI: 10.3390/ijms25052554.


Subclinical Target Organ Damage in a Sample of Children with Autosomal Dominant Polycystic Kidney Disease: A Pilot Study.

Romano S, Marcon D, Branz L, Tagetti A, Monami G, Giontella A Medicina (Kaunas). 2023; 59(10).

PMID: 37893495 PMC: 10608453. DOI: 10.3390/medicina59101777.